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BY-NC-ND license (http://creativecomBackground/Purpose: Cholangiocarcinoma (CC) is a fatal malignancy originating from biliary
tracts and constitutes approximately 10e20% of hepatobiliary cancers. CC is characterized
by a very poor prognosis. The definite molecular mechanisms leading to oncogenesis remain
unclear. This study aimed to perform mutation analysis and copy number changes of KRAS
and BRAF genes of CC in Taiwan.
Methods: A total of 182 cases of biliary tact CC were studied for point mutation and quantita-
tive real-time polymerase chain reaction analysis of KRAS and BRAF genes. The obtained data
were analyzed with clinical and histopathological variables and survival.
Results: KRAS point mutations were detected in intrahepatic CC (7.6%), common bile duct can-
cer (13.3%), and gallbladder carcinoma (3.3%). BRAF gene amplifications were demonstrated in
intrahepatic CC (4.3%), common bile duct cancer (3.3%), and gallbladder cancer (5%). No asso-
ciation was observed between mutation patterns and histopathological features. The analyses
of risk factors for overall survival in patients with CC revealed no significant association in age,
tumor site, genetic mutation, or amplifications. The tumor stage was the significant prognostic
factor.
Conclusion: Unlike other studies from American, European, or Japanese groups which showed
certain levels of gene mutations in CC, our data revealed a rather low frequency of KRAS mu-
tations and BRAF gene amplifications in CC in Taiwan. Tumor TNM stage was the only significantave no conflicts of interest relevant to this article.
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Cholangiocarcinoma (CC) is a fatal malignant neoplasm
originating from intrahepatic (ICC) and extrahepatic (ECC)
biliary tracts.1 It accounts for approximately 10e20% of
hepatobiliary cancers, and is characterized by a poor
prognosis.2 The incidences and mortality rates have
increased during the past decades.3 A high prevalence in
Southeast Asia and Eastern Asia has been observed.3,4 CC
rarely occurs before the age of 40 years and the median age
at presentation is > 65 years, with a slight male
predominance.2e4
Several recognized risk factors account for a minority of
CC. Hepatobiliary flukes of the species Clonorchis sinensis
and Opisthorchis viverrini are associated with the devel-
opment of CC, particularly in Southeast Asia.3,5 Hep-
atolithiasis and viral hepatitis are common risk factors for
intrahepatic CC in Asian countries.2,4,6,7 Patients diagnosed
with primary sclerosing cholangitis carry an increased risk
of ICC and ECC in Western countries.1,8,9
Anatomically, CC can be classified into intrahepatic,
perihilar, and distal extrahepatic biliary tract cancers. Ac-
cording to the growth pattern, three subtypes of mass-
forming, periductal-infiltrating, and intraductal growth
patterns, have been identified.10 At present, the definite
cellular and molecular mechanisms leading to oncogenesis
of CC remain unclear. An important contributor to the
malignant transformation of cholangiocytes is chronic
inflammation. Persistent inflammation may induce tumori-
genesis by causing damage in protooncogenes, DNA
mismatch repair genes, tumor suppressor genes, and
accumulation of somatic mutations.11,12
Studies from American, European, and Japanese groups
have described that activating KRAS and BRAF mutations
play a role in the carcinogenesis of CC of the biliary
tracts.13e20 In the study, we investigate the mutation
analysis and copy number changes of KRAS and BRAF genes
in 182 patients in Taiwan. Additionally, we have also
compared the associations of the molecular alterations
with the clinicopathological features of the examined
carcinomas.Materials and methods
Patients and tissue specimens
The institutional review board had approved the procure-
ment of formalin-fixed tissue in the study. Available
paraffin-embedded tissue blocks have been retrieved from
182 patients from the Department of Pathology, Far Eastern
Memorial Hospital and National Taiwan University Hospitaluang W-C, et al., Mutation analysi
rcinoma, Journal of the Formbetween 1998 and 2012 (IRB-099084). Ninety-two intra-
hepatic CCs, 30 common bile duct (CBD) cancers, and 60
gallbladder adenocarcinomas were included for compari-
son. There were 83 men and 99 women, with a mean age of
60.6 years (range 33e90 years). Ninety patients in this
study were recruited from the previous study.21 The clinical
and follow-up information was obtained from medical
records.DNA preparation and polymerase chain reaction
analysis of genetic mutation
DNA was extracted from formalin-fixed, paraffin-embedded
tissue samples. Using the method of microdissection, we
chose the areas with tumor cellularity more than 80% in
order to extract the genomic DNA by using a QIAamp DNA
FFPE Tissue Kit (Qiagen, Santa Clarita, CA, USA), following
the manufacturer’s instructions. KRAS was amplified by
polymerase chain reaction (PCR) using the following
primers: KRAS-F, GAATGGTCCTGCACCAGTAA; and KRAS-R,
GTGTGACATGTTCTAATATAGTCA. After purification, direct
sequencing was accomplished using an automated ABI 3770
sequencer (Applied BioSystems, Foster City, CA, USA).
Quantitative real-time PCR (qPCR) using an ABI7900 with
SYBR green dye (Molecular Probes) was performed to check
the gDNA copy number of candidate genes.22,23 Real-time
PCR reactions were accomplished in triplicate, and
threshold cycle numbers were averaged. The difference
between the threshold cycle number of KRAS and BRAF
genes, and the threshold cycle number of the control group
were obtained. The qPCR primers sequences were: KRAS-F1,
GCCTGCTGAAAATGACTGAA; KRAS-R1, TTGTTGGATCA-
TATTCGTCCAC; KRAS-F2, CTCGGAGCTCGATTTTCCTA; KRAS-
R2, GTCCGCTCCGTACCTCTCTC; BRAF-F1, TGCTTGCTCTGA-
TAGGAAAATGA; BRAF-R1, CCACAAAATGGATCCAGACAAC;
BRAF-F2, CCCGGCTCTCGGTTATAAGA; and BRAF-R2,
CCGCCTCTTTCCAAAATAAA.Statistical analyses
The statistical analyses were conducted using PASW Sta-
tistics version 18.0.2 (IBM Corporation, Armonk, NY, USA).
The association between KRAS mutation, KRAS amplifica-
tion, BRAF gene amplification, and other clinicopathologic
parameters was evaluated using the c2 test. The influences
of mutation, amplification, and other clinicopathological
parameters on overall survival (OS) were analyzed by Cox
proportional hazard model, and p values from Wald statis-
tics were recorded. The KaplaneMeier method and log-rank
tests were performed to evaluate prognostic differences
between groups. The cutoff of significance level was 0.05.s and copy number changes of KRAS and BRAF genes in Taiwanese
osan Medical Association (2016), http://dx.doi.org/10.1016/
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KRAS and BRAF mutation analysis and copy number
changes in the patients
Table 1 showed the correlation of genetic mutations, am-
plifications, and clinicopathological factors. These 182
cases of CC consisted of 92 ICCs, 30 CBD cancers, and 60
gallbladder adenocarcinomas. KRAS point mutations were
detected in 13 cases: seven in ICCs (7.6%), four in CBD
cancer (13.3%), and two in gallbladder cancer (3.3%). All
KRAS mutations were located at codon 12. The types of
KRAS codon 12 mutations included five cases of G12D, from
a glycine (G) to an aspartic acid (D); four cases of G12C,
from a glycine (G) to a cysteine (C); three cases of G12S,
from a glycine (G) to a serine (S); and one case of G12R,
from a glycine (G) to an arginine (R).
Both pairs of qPCR primers with amplification were
required to identify copy number gain. KRAS gene am-
plifications were demonstrated in 21 cases: seven in ICCs
(7.6%), four in CBD cancers (13.3%), and 10 in gallbladder
cancers (16.6%). Three cases expressed KRAS point mu-
tation and copy number changes simultaneously; twoTable 2 Univariate analysis of risk factors for overall
survival in patients with cholangiocarcinoma.
Covariate No. Overall survival
HR (95% CI) p
Age (y) 0.11
 65 93 1.00
> 65 89 1.32 (0.94e1.86)
Sex 0.50
Female 99 1.00
Male 83 1.13 (0.80e1.59)
Site
Intrahepatic 92 1.00 0.17
Extrahepatic 90 1.00 (0.71e1.41) > 0.99
CBD 30 0.73 (0.44e1.20)
Gallbladder 60 1.19 (0.81e1.73)
KRAS mutation 0.73
No 169 1.00
Yes 13 0.89 (0.47e1.70)
KRAS amplification 0.28
No 161 1.00
Yes 21 0.74 (0.43e1.28)
KRAS mutation and/
or amplification
0.20
No 151 1.00
Yes 31 0.74 (0.47e1.18)
BRAF amplification 0.66
No 174 1.00
Yes 8 0.83 (0.37e1.90)
Stage < 0.001
I 44 1.00
II 52 2.23 (1.28e3.86)
III 76 4.04 (2.40e6.80)
IV 10 19.27 (8.44e44.00)
CBDZ common bile duct; CIZ confidence interval; HRZ ha-
zard ratio.
s and copy number changes of KRAS and BRAF genes in Taiwanese
osan Medical Association (2016), http://dx.doi.org/10.1016/
Figure 1 KaplaneMeier estimate of overall survival curves by
stage in patients with cholangiocarcinoma. OSZ overall
survival.
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+ MODELcases from gallbladder cancers and one case from CBD
cancers. Eight BRAF gene amplifications were found: four
cases in ICCs (4.3%), one case in CBD cancer (3.3%), and
three cases in gallbladder cancer (5%). Our data revealed
low frequency of KRAS mutations and BRAF gene ampli-
fications in the ICC, ECC, and gallbladder carcinoma in
Taiwan.
Clinicopathological variables and prognostic impact
of genetic mutation and amplifications in CC
Forty-four cases were classified as Stage I, 52 cases as Stage
II, 76 cases as Stage III, and 10 cases as Stage IV. The uni-
variate analyses (Table 2) of risk factors for OS in patients
with CC revealed no significant association in age, tumor
site, genetic mutation, and amplifications. The tumor stage
was the significant prognostic parameters of OS in
KaplaneMeier analysis (Figure 1). In multivariate analyses
(Table 3), tumor stage still remained as the most powerful
prognostic factor.
Discussion
CC is the second most common primary hepatic tumor after
hepatocellular carcinoma. The prevalence rates vary
markedly worldwide in different racial groups, presumably
reflecting differences in local risk factors.3e9 Hep-
atolithiasis is more commonly found in Asia than in Western
countries, accounting for around 2e10% of the incidence
rate of CC.2,4,6 Cirrhosis from viral hepatitis or any cause is
associated with an increased risk of CC in Asian coun-
tries.2,4 Other rarer conditions associated with CC mayTable 3 Multivariate analysis of risk factors for overall survival
Covariate Parameter estimate Standard erro
Stage
Stage II vs. I 0.800 0.280
Stage III vs. I 1.395 0.266
Stage IV vs. I 2.959 0.421
CIZ confidence interval; HRZ hazard ratio.
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j.jfma.2016.07.015include toxins and biliary tract disorders, such as chol-
edochal cyst and Caroli disease (cystic dilatation of intra-
hepatic bile ducts).2,9
Few studies have addressed clinicopathological and
mutation analysis correlations. KRAS mutations have been
found in ICC and ECC with variable incidence rates in
different geographical areas.13e18 Rare reports of BRAF
mutation analysis have been done in biliary tract cancers in
the literature.19,20 The RAS gene product has a key role in
controlling cell growth and differentiation through its
intrinsic GTPase activity.24 Both KRAS and BRAF are mem-
bers of the RASeRAFeMEKeERKeMAP kinase pathway
which mediates cellular response to growth signals.25 In the
literature, the reported mutation rates of KRAS were
20e54% for intrahepatic CC, 8.3e100% for extrahepatic bile
duct carcinomas, and 0e33% for gallbladder
carcinomas.13e18 Our data revealed low KRAS point muta-
tion rates in intrahepatic CC (7.6%), CBD cancer (13.3%), or
gallbladder carcinoma (3.3%). KRASmutation analysis in our
cases mostly displayed a high mutation rate, up to 80%, in
the pancreatic adenocarcinoma (unpublished data). In the
literature, KRAS mutations have been detected more
frequently in pancreatic ampullary adenocarcinomas with
precursor adenomatous lesions than those without.26,27
These results may suggest that pancreatic ampullary car-
cinomas develop from a KRAS dependent pathway with an
adenomaecarcinoma sequence.
Rare BRAF gene amplifications, ICCs (4.3%), CBD cancers
(3.3%), and gallbladder carcinomas (5%), have been detec-
ted in our patients. Our data has been the largest study of
BRAF mutation analysis for the ICC, ECC, and gallbladder
carcinomas so far. The previous data on BRAF mutation
frequency were contradictory. Few series demonstrated no
BRAF mutations in the biliary tract cancers and gallbladder
carcinoma.20,28 However, a study from Europe reported a
33% BRAF mutation rate in patients with gallbladder carci-
noma,29 and a 22% mutation rate in intrahepatic CC.19 These
results may suggest potential different geographic influence
factors on BRAF mutational frequency.
In the current study, we could not substantiate the as-
sociations of genetic mutation with the OS. No specific as-
sociation between KRAS or BRAF mutation and
histopathological features was observed. The extent of the
primary tumor, presence of lymph node metastases, and
tumor stage were the significant prognostic parameters. A
study reported KRAS mutation status as a prognostic factor
for patients with biliary tract cancers,16 but another study
did not demonstrate the association.30
The prognosis of CC is poor and the median survival of
patients with unresectable tumor is around 6e12 months.in patients with cholangiocarcinoma.
r Wald c2 p HR (95% CI)
8.134 0.004 2.23 (1.28e3.86)
27.494 < 0.001 4.04 (2.40e6.80)
49.319 < 0.001 19.27 (8.44e44.00)
s and copy number changes of KRAS and BRAF genes in Taiwanese
osan Medical Association (2016), http://dx.doi.org/10.1016/
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only applicable in a minority of patients.2,18 Photodynamic
therapy is a recommendable approach for palliative ther-
apy.18 No curative chemotherapeutic regimen is available
so far. Recently, the trial demonstrated improvements in
overall and progression-free survival with the combination
chemotherapy of gemcitabine and cisplatin compared to
gemcitabine alone in patients with locally advanced or
metastatic biliary tract cancer.31 Due to the heterogeneity
of tumor anatomic sites, histopathological subtypes,
different geographical etiopathogenesis, and molecular
pathways of biliary tract cancers, it is crucial to develop
the targeted therapies from more prospective studies of
multidisciplinary and multi-institutional cooperation.
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